rituximab,ibrutinib,Bendamustine
biogen,roche,janssen,abbvie,teva pharmaceuticals,novartis
['lymsm', 'rituximab', 'shine']
ibrutinib combined with bendamustine and rituximab extended the highest progression-free survival rate ever reported for this patient population, in the phase 3 shine study. #asco22 #mcl #lymsm 
Oncology news and insights from leading researchers and cancer centers.